



Pharmaron Beijing Co., Ltd.

Pharmaron Beijing Co., Ltd. (the “Issuer”)

USD 300 Million Zero Coupon Convertible Bonds due 2026

(ISIN: XS2352395748) and

RMB 1,916 Million USD Settled Zero Coupon Convertible Bonds due 2026

(ISIN: XS2353011724)

(together, the “Bonds”)

Notice to the Bondholders

Unless otherwise defined herein, capitalized terms in this notice shall have the same meanings as those defined in the terms and conditions of the Bonds (the “**Conditions**”), and the circular of the Issuer to be dated and published on or around August 30, 2023 on the websites of The Stock Exchange of Hong Kong Limited (www.hkexnews.hk) and the Issuer (www.pharmaron.com).

Closure of Register of Shareholders

In accordance with the respective Trust Deed of the Bonds executed on June 18, 2021 and pursuant to the Conditions, the Issuer hereby wishes to inform you that the Issuer’s register of Shareholders (the “**Register of Shareholders**”) will be closed from Tuesday, September 12, 2023 to Friday, September 15, 2023 (both days inclusive) for determining the H Shareholders entitled to attend and vote at the EGM, and re-opened on Monday, September 18, 2023.

(the “**Closure**”).

Conversion Restriction Period

Pursuant clause 5.1.1 of the Conditions, the Issuer also wishes to inform you that the Conversion Right may not be exercised for any Bonds during the following periods:

- (a) between Thursday, August 31, 2023 and Friday, September 15, 2023 (both days inclusive), i.e., commencing on the date falling 15 days prior to the EGM and ending on the date of that EGM ;
- (b) during the periods of Closure above, i.e., commencing on such date and for such period as determined by applicable law from time to time that the Issuer is required to close its register.

(the “**Conversion Restriction Period**”)

For the purpose of this notice, “working day” means a day other than a Saturday, Sunday or a public holiday on which commercial banks and foreign exchange markets are open for business in London.

In the event of any amendments to the Conversion Restriction Period, the Issuer shall notify you in writing promptly upon the confirmation of any such amendments.

Any Bondholder who is in doubt as to the action to be taken should consult his/her/its stockbroker, bank manager, solicitor, professional accountant or other professional adviser.

For and on behalf of
Pharmaron Beijing Co., Ltd.
(康龙化成(北京)新药技术股份有限公司)



Authorised Signatory

Name: LI Shing Chung Gilbert

Title: Chief Financial Officer

8th Floor, Block 1

6 Tai-He Road

Beijing Economic Technological Development Area

Beijing, China